Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 9/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18598985 | 1.00 | NR1H2 (0.42) | NR1H2CHRM2CHRM1CHRM3RORC | |
| SCHEMBL24695414 | 0.86 | NR1H2 (0.41) | NR1H2RORCEPHX2USP2SMN1; SMN2 | |
| SCHEMBL27171881 | 0.86 | NR1H2 (0.41) | NR1H2RORCEPHX2USP2SMN1; SMN2 | |
| SCHEMBL24087434 | 0.86 | NR1H2 (0.41) | NR1H2RORCEPHX2USP2SMN1; SMN2 | |
| SCHEMBL22620486 | 0.86 | CHRM2 (0.44) | NR1H2CHRM2CHRM1CHRM3RORC | |
| SCHEMBL28708135 | 0.83 | RORC (0.41) | NR1H2CHRM2CHRM1CHRM3RORC | |
| SCHEMBL31279448 | 0.83 | EPHX2 (0.43) | NR1H2CHRM2CHRM1CHRM3RORC | |
| SCHEMBL26961826 | 0.83 | EPHX2 (0.43) | NR1H2CHRM2CHRM1CHRM3RORC | |
| SCHEMBL31637109 | 0.81 | NR1H2 (0.40) | NR1H2RORCEPHX2USP2SMN1; SMN2 | |
| SCHEMBL30278337 | 0.81 | APLNR (0.43) | NR1H2RORCEPHX2USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022123-A1 | Methods of Making Modified BTK Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2026-01-22 | — | — | US | disclosed |
| CN-119343340-A | Methods of preparing modified BTK inhibitors | 普林斯匹亚生物制药公司 | 2025-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022123-A1 | Methods of Making Modified BTK Inhibitors | BTK, TEC, SYK | NR1H2 2430/4885CHRM2 2940/4885CHRM1 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.